盐酸阿罗洛尔对慢性肾脏病合并高血压的疗效观察及脂质代谢的影响

Efficacy of Arotinolol in treating patients combining hypertension and V-stage chronic kidney disease and its effect on lipid metabolism

目的观察α、β受体抑制剂盐酸阿罗洛尔对慢性肾脏病Ⅴ期合并高血压患者降压疗效、安全性,及脂质代谢的影响。方法选择60例慢性肾脏病Ⅴ期合并高血压患者,随机分为治疗组38例和对照组22例。所有患者维持原降压治疗,治疗组在此基础上加用盐酸阿罗洛尔,起始剂量10mg、1次/d,根据血压情况逐渐增加至10mg、2次/d,治疗时间4周。观察两组患者治疗前后血压、心率及血脂代谢指标的变化。结果 4周后,治疗组患者血压、心率明显下降,与其治疗前及对照组比较均有统计学意义(P<0.01);血脂代谢指标无显著变化(P>0.05)。结论盐酸阿罗洛尔对慢性肾脏病Ⅴ期合并高血压患者有治疗效果,对脂质代谢的异常无加剧作用。

Objective To observe the efficacy of Arotinolol in treating V-stage chronic kidney disease （CKD） patients incorporated with hypertension and its effect on lipid metabolism. Methods We selected 60 V-stage CKD patients incorporated with hypertension who were randomly divided into treatment group （38 patients） and control group （22 patients）. The treatment group＇s initial dose of Arotinolol was 10 mg daily, and the dose of Arotinolol was increased gradually to 10 mg twice daily for four weeks. The change of blood pressure, heart rate and lipid index were observed before and after using Arotinolol. Results Arotinolol could control blood pressure effectively and decrease heart rate; and it had no influences on lipid profile. Conclusions Arotinolol is safe and effective to cure V-stage CKD patients incorporated with hypertension. Arotinolol had no influence on lipid metabolism.